Ring study 3 used a subset of H&E slides from NSABP-B31, an older completed trial evaluating benefit of trastuzumab in early HER2-positive breast cancer, which started accrual in February 2000 across multiple centers. This evidence concerns the gene ERBB2 and breast carcinoma.